Your browser doesn't support javascript.
loading
Impact of COPD on mortality: An 8-year observational retrospective healthcare claims database cohort study.
Vogelmeier, Claus F; Friedrich, Felix W; Timpel, Patrick; Kossack, Nils; Diesing, Joanna; Pignot, Marc; Abram, Melanie; Halbach, Marija.
Afiliação
  • Vogelmeier CF; Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, German Center for Lung Research (DZL), Baldingerstraße, 35033, Marburg, Hessen, Germany.
  • Friedrich FW; AstraZeneca GmbH, Friesenweg 26, 22763, Hamburg, Germany.
  • Timpel P; WIG2 GmbH Scientific Institute for Health Economics and Health System Research, Markt 8, 04109, Leipzig, Sachsen, Germany.
  • Kossack N; WIG2 GmbH Scientific Institute for Health Economics and Health System Research, Markt 8, 04109, Leipzig, Sachsen, Germany.
  • Diesing J; WIG2 GmbH Scientific Institute for Health Economics and Health System Research, Markt 8, 04109, Leipzig, Sachsen, Germany.
  • Pignot M; ZEG - Center for Epidemiology and Health Research Berlin GmbH, Invalidenstraße 115, 10115, Berlin, Germany.
  • Abram M; AstraZeneca GmbH, Friesenweg 26, 22763, Hamburg, Germany.
  • Halbach M; AstraZeneca GmbH, Friesenweg 26, 22763, Hamburg, Germany. Electronic address: marija.halbach@astrazeneca.com.
Respir Med ; 222: 107506, 2024 Feb.
Article em En | MEDLINE | ID: mdl-38151176
ABSTRACT

BACKGROUND:

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality. Here we present a large observational study on the association of COPD and exacerbations with mortality (AvoidEx Mortality).

METHODS:

A real-world, observational cohort study with longitudinal analyses of German healthcare claims data in patients ≥40 years of age with a COPD diagnosis from 2011 to 2018 (n = 250,723) was conducted. Patients entered the cohort (index date) upon the first COPD diagnosis. To assess the impact of COPD on all-cause death, a propensity score-matched control group of non-COPD patients was constructed. The number and severity of exacerbations during a 12-month pre-index period were used to form subgroups. For each exacerbation subgroup the exacerbations during 12 months prior to death were analysed.

RESULTS:

COPD increases the all-cause mortality risk by almost 60% (HR 1.57 (95% CI 1.55-1.59)) in comparison to matched non-COPD controls, when controlling for other baseline covariates. The cumulative risk of death after 8 years was highest in patients with a history of more than one moderate or severe exacerbation. Among all deceased COPD patients, 17.2% had experienced a severe, and 34.8% a moderate exacerbation, within 3 months preceding death. Despite increasing exacerbation rates towards death, more than the half of patients were not receiving any recommended pharmacological COPD therapy in the year before death.

CONCLUSION:

Our study illustrates the impact of COPD on mortality risk and highlights the need for consequent COPD management comprising exacerbation assessment and treatment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença Pulmonar Obstrutiva Crônica Limite: Adult / Humans / Middle aged Idioma: En Revista: Respir Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença Pulmonar Obstrutiva Crônica Limite: Adult / Humans / Middle aged Idioma: En Revista: Respir Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha